Prophylaxis and von Willebrand's disease (vWD)

Thrombosis Research

Volumn 118, Issue SUPPL. 1, 2006, Pages

  Abshire, Thomas C ^a  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

Arthropathy; Factor VIII; Haemorrhage; Prophylaxis; Synovitis; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; STEROID; VON WILLEBRAND FACTOR;

ANKLE; ARTHRALGIA; ARTHROPATHY; ARTICLE; BLEEDING DISORDER; CAST APPLICATION; GENETIC DISORDER; HEMARTHROSIS; HIP; HUMAN; JOINT DEGENERATION; JOINT EFFUSION; JOINT SWELLING; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANGE OF MOTION; RECURRENT DISEASE; SYNOVITIS; THROMBOCYTE ADHESION; VON WILLEBRAND DISEASE;

HEMORRHAGE; HUMANS; JOINT DISEASES; PREMEDICATION; VON WILLEBRAND DISEASE;

EID: 33646061372     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.01.014     Document Type: Article

References (18)

1. Rodeghiero F., Castaman G., and Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69 (1987) 454-459
2. Werner E.J., Broxson E.H., Tucker E.L., Giroux D.S., Shults J., and Abshire J.C. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 123 (1993) 893-898
3. Mannucci M. Treatment of von Willebrand's disease. N Engl J Med 351 (2004) 683-694
4. Berntorp E., and Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 16 S1 (2005) S23-S26
5. Berntorp E., Baghaei F., Homström M., Lethagen S., Stigendal L., and Petrini P. Long-term prophylaxis in vWD. The Swedish experience. J Thromb Haemost 3 S1 (2005) P0872 [Abstract]
6. Mannucci P.M., Chediak J., Hanna W., Byrnes J., Ledford M., Ewenstein B.M., et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99 (2002) 450-456
7. ®) in preventing bleeding during surgery or invasive procedures in patients with won Willebrand's disease. Hematologica 88 (2003) 1279-1283
8. Centers for Disease Control and Prevention. The universal data collection project (2005). http://www.cdc.gov/ncbddd/hbd/surveillance.htm http://www.cdc.gov/ncbddd/hbd/surveillance.htm
9. Soucie J.M., Cianfrini C., Janco R.L., Kulkarni R., Hambleton J., Evatt B., et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 103 (2004) 2467-2473
10. Nilsson I.M., Hedner U., and Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 65 (1976) 129-135
11. Poncia H.D., and Ryan J. An acutely painful elbow as a first presentation of von Willebrand's disease. J Accid Emerg Med 16 (1999) 153-154
12. Macfarlane J.D., Kroon H.M., and Caekebeke-Peerlinck K.M. Arthropathy in von Willebrand's disease. Clin Rheumatol 8 (1989) 98-102
13. Sankarankutty M., and Evans D.I. Chronic arthropathy in von Willebrand's disease. Clin Lab Haematol 5 (1983) 149-156
14. Lak M., Peyvandi F., and Mannucci P.M. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 111 (2000) 1236-1239
15. Morris C.J., Blake D.R., Wainwright A.C., and Steven M.M. Relationship between iron deposits and tissue damage in the synovium: an ultrastructural study. Ann Rheum Dis 45 (1986) 21-26
16. Wien F.-Q., Jabbar A.A., Chen Y.-X., Kazarian T., Patel D.A., and Valentino L.A. c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide. Blood 100 (2002) 912-916
17. Hakobyan N., Kazarian T., Jabbar A.A., Jabbar K.J., and Valentino L.A. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 104 (2004) 2060-2064
18. Roosendaal G., Vianen M.E., Wenting M.J.G., van Rinsum A.C., van den Berg H.M., Lafeber F.P.J.G., et al. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J Bone Joint Surg Br 80 (1998) 540-545